β-catenin plus PROX1 immunostaining stratifies disease progression and patient survival in neoadjuvant-treated pancreatic cancer.

Annika EurolaAri RistimäkiHarri MustonenAnna-Maria NurmiJaana HagströmPauliina KallioKari AlitaloCaj HaglundHanna Seppänen

Published in: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2022)

Strong β-catenin immunopositivity and combined strong or moderate β-catenin and PROX1 immunopositivity associated with improved survival among the good NAT-responders and worse survival among the poor NAT-responders.

Keyphrases

epithelial mesenchymal transition
cell proliferation
lymph node
rectal cancer
high intensity
signaling pathway
newly diagnosed